The global phase III trial MARIPOSA‐2 evaluated the combination of amivantamab (EGFR/MET bispecific monoclonal antibody) plus carboplatin–pemetrexed chemotherapy, with and without lazertinib, in patients with EGFR‐mutated advanced NSCLC after progression on osimertinib. This evidence concerns the gene MET and non-small cell lung carcinoma.